Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) EBITDA: 2023-2025

Historic EBITDA for Tonix Pharmaceuticals Holding (TNXP) over the last 2 years, with Sep 2025 value amounting to -$33.1 million.

  • Tonix Pharmaceuticals Holding's EBITDA fell 112.59% to -$33.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$99.9 million, marking a year-over-year increase of 29.43%. This contributed to the annual value of -$136.7 million for FY2024, which is 15.48% down from last year.
  • Tonix Pharmaceuticals Holding's EBITDA amounted to -$33.1 million in Q3 2025, which was down 16.86% from -$28.3 million recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's EBITDA ranged from a high of -$15.6 million in Q3 2024 and a low of -$77.3 million during Q2 2024.
  • Its 3-year average for EBITDA is -$30.0 million, with a median of -$27.3 million in 2023.
  • Within the past 5 years, the most significant YoY rise in Tonix Pharmaceuticals Holding's EBITDA was 63.40% (2025), while the steepest drop was 112.59% (2025).
  • Quarterly analysis of 3 years shows Tonix Pharmaceuticals Holding's EBITDA stood at -$27.3 million in 2023, then rose by 17.74% to -$22.5 million in 2024, then slumped by 112.59% to -$33.1 million in 2025.
  • Its EBITDA stands at -$33.1 million for Q3 2025, versus -$28.3 million for Q2 2025 and -$16.1 million for Q1 2025.